PayPal Holdings Inc

PayPal Holdings Inc (NYSE: PYPL) is a major technology platform and digital payments company. The company allows digital and mobile payments on behalf of merchants and consumers globally. PYPL’s overall payment solutions comprise its core PayPal and PayPal Credit, Braintree, Venmo, Xoom, Zettle, and Hyperwallet products and services, including its proprietary Payments Platform.

Financial and Operational Update: On 3 December 2021, the company updated that it processed the highest $188 million in donations globally this Giving Tuesday. Over 1.6 million PayPal customers spread over 193 markets donated to causes they care about, resulting in more than 2.1 million donations. Besides, on 1 December 2021, the company mentioned that the US-based Wix merchants could provide PayPal Pay in 4 and PayPal Credit to its consumers. It will be offered through a dedicated Pay Later checkout button and present Pay in 4 messaging earlier in the shopping journey. On the financial front, PYPL has delivered a robust performance across financial metrics with net revenue of $6.18 billion in Q3FY21, increasing 13% on a spot and FXN basis. GAAP EPS stood at $0.92 compared to $0.86 in Q3FY20. It generated an operating cash flow of $1.51 billion, up 15%. The company has inducted 13.3 million net new active accounts, thus ending the quarter with 416 million active accounts.

Technical Analysis

Daily Price Chart

Note: The purple colour line in the chart depicts RSI (14-period). The sky-blue and red-colour lines show 21-Period SMA and 50-Period SMA, respectively.

On the daily chart, PYPL's price has had a severe fall since achieving a double top in July 2021. Because the market is encountering significant resistance at higher levels, we can only anticipate the rising trend to continue if the price breaks out over USD 204.48 with volume. The stock's next key support level is now USD 171.63, followed by USD 152.22.

Stock Recommendation

The company forecasts achieving revenue between ~$25.3 billion to ~$25.4 billion, translating to a growth of ~18% at current spot rates and ~17% on an FXN basis. Further, it estimates attaining GAAP EPS of ~$3.62 compared to $3.54 in FY’20, and non-GAAP EPS is expected to grow ~19% to ~$4.60. Additionally, the company expects to achieve more than 430 million active accounts at the end of FY21. TPV growth is expected to stay between ~33%-34% at current spot rates and ~31%-32% on an FXN basis.

Therefore, considering the facts above and the current trading levels, we give a “Watch” recommendation on the stock at the closing market price of US$187.16, down 2.08% as of 5th January 2022.

Zomedica Corp

Zomedica Corp (NYSE: ZOM) is an animal health company and is involved in catering to clinical veterinarians' requirements in ways that promote both patient and practice health. The company aims to advance veterinary practitioners' effectiveness and financial well-being by providing professionally beneficial diagnostic products and services.

Financial and Operational Update: On October 4, 2021, the company announced the appointment of Mr. Larry Heaton as President effective October 1, 2021. Mr. Heaton adopted the role of Chief Executive Officer post the retirement of Robert Cohen from the post on October 31, 2021. Besides, on October 1, 2021, the company has declared that it had acquired the Pulse Veterinary Technologies businesses for $70.9 million in an all-cash stock transaction. Through this acquisition, ZOM expects its existing sales organization will add PulseVet’s small animal products to its product portfolio that will assist in fast-tracking the growth of the X-Trode. On the financial front, ZOM has generated revenue of $22,514 and $52,331 for the three and nine months ended September 30, 2021, respectively. It posted a net and comprehensive loss of approximately $6.3 million and $15.1 million for the three and nine months ended September 30, 2021. Compared to a net loss and total loss of around $5.0 million and $12.7 million, the three and nine months ended September 30, 2020, respectively.

Technical Analysis

Daily Price Chart

Note: The purple colour line in the chart depicts RSI (14-period). The sky-blue and red-colour lines show 21-Period SMA and 50-Period SMA, respectively.

On the daily chart, ZOM's price has been trading in a falling channel for a long time, and the RSI on the daily chart is showing divergence, therefore we may expect an up move in the stock once it breaks out over USD 0.38, backed by volumes. The stock's next key support level appears to be USD 0.26, followed by USD 0.23.

Stock Recommendation

The company will continue working with its partner, Qorvo Biotechnologies, to develop new assays for the TRUFORMA® instrument and is likely to release various new assays to market in 2022. Further, ZOM will sustain its strategy to expand its product offerings and technologies and product development efforts. Besides, the company holds cash and cash equivalents of approximately $271.4 million as of September 30, 2021.

Therefore, considering the facts above and the current trading levels, we give a “Watch” recommendation on the stock at the market price of US$0.33, down 6.29% as of January 5 2022.

Note 1: The reference data in this report has been partly sourced from REFINITIV.

Note 2: Investment decisions should be made depending on the investors’ appetite on upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the analysis has been achieved and subject to the factors discussed above alongside support levels provided.

Technical Indicators Defined:-

Support: A level where-in the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.

Resistance: A level where-in the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.

Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.